End-of-day quote
Korea S.E.
03:30:00 05/07/2024 am IST
|
5-day change
|
1st Jan Change
|
6,430
KRW
|
+1.42%
|
|
+3.54%
|
-35.05%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
14,85,081
|
30,69,933
|
14,59,198
|
4,70,211
|
4,10,353
|
Enterprise Value (EV)
1 |
14,41,942
|
30,90,374
|
14,83,621
|
5,32,352
|
4,13,298
|
P/E ratio
|
-80.7
x
|
142
x
|
-30.2
x
|
-8.34
x
|
-5.99
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
131
x
|
166
x
|
39.6
x
|
29.1
x
|
92.7
x
|
EV / Revenue
|
128
x
|
167
x
|
40.3
x
|
33
x
|
93.4
x
|
EV / EBITDA
|
-34.3
x
|
-85.3
x
|
-93.9
x
|
-18.5
x
|
-11.2
x
|
EV / FCF
|
-
|
-10,20,01,939
x
|
-3,07,63,335
x
|
-55,00,948
x
|
-1,36,46,659
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
5
x
|
5.73
x
|
2.84
x
|
1.72
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
30,890
|
32,107
|
32,538
|
32,688
|
41,450
|
Reference price
2 |
48,077
|
95,615
|
44,846
|
14,385
|
9,900
|
Announcement Date
|
12/03/21
|
12/03/21
|
17/03/22
|
20/03/23
|
13/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
11,303
|
18,543
|
36,828
|
16,139
|
4,427
|
EBITDA
1 |
-42,070
|
-36,231
|
-15,801
|
-28,808
|
-36,897
|
EBIT
1 |
-44,573
|
-39,151
|
-19,099
|
-33,680
|
-41,928
|
Operating Margin
|
-394.35%
|
-211.13%
|
-51.86%
|
-208.69%
|
-947.19%
|
Earnings before Tax (EBT)
1 |
-16,509
|
27,536
|
-48,876
|
-56,831
|
-66,860
|
Net income
1 |
-16,509
|
27,570
|
-48,042
|
-55,974
|
-66,874
|
Net margin
|
-146.06%
|
148.68%
|
-130.45%
|
-346.82%
|
-1,510.71%
|
EPS
2 |
-595.4
|
671.5
|
-1,483
|
-1,724
|
-1,652
|
Free Cash Flow
|
-
|
-30,297
|
-48,227
|
-96,775
|
-30,286
|
FCF margin
|
-
|
-163.38%
|
-130.95%
|
-599.63%
|
-684.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/21
|
12/03/21
|
17/03/22
|
20/03/23
|
13/03/24
|
Fiscal Period: December |
2023 Q3
|
---|
Net sales
1 |
0.357
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
15/11/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
20,441
|
24,423
|
62,141
|
2,945
|
Net Cash position
1 |
43,139
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.5642
x
|
-1.546
x
|
-2.157
x
|
-0.0798
x
|
Free Cash Flow
|
-
|
-30,297
|
-48,227
|
-96,775
|
-30,286
|
ROE (net income / shareholders' equity)
|
-
|
6.61%
|
-9.26%
|
-14.3%
|
-23.3%
|
ROA (Net income/ Total Assets)
|
-
|
-5.12%
|
-1.94%
|
-4.1%
|
-6.85%
|
Assets
1 |
-
|
-5,38,051
|
24,82,781
|
13,63,655
|
9,76,584
|
Book Value Per Share
2 |
9,612
|
16,682
|
15,795
|
8,341
|
7,156
|
Cash Flow per Share
2 |
617.0
|
162.0
|
854.0
|
549.0
|
146.0
|
Capex
1 |
3,962
|
22,208
|
56,433
|
31,747
|
7,273
|
Capex / Sales
|
35.05%
|
119.76%
|
153.23%
|
196.71%
|
164.3%
|
Announcement Date
|
12/03/21
|
12/03/21
|
17/03/22
|
20/03/23
|
13/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -35.05% | 193M | | +16.61% | 122B | | +17.75% | 112B | | +17.23% | 25.91B | | -24.11% | 19.33B | | -18.56% | 16.17B | | -18.47% | 15.6B | | -47.75% | 14.65B | | +57.35% | 14.34B | | +5.62% | 14B |
Bio Therapeutic Drugs
|